Verrica Pharmaceuticals Inc
NASDAQ:VRCA

Watchlist Manager
Verrica Pharmaceuticals Inc Logo
Verrica Pharmaceuticals Inc
NASDAQ:VRCA
Watchlist
Price: 0.694 USD 2.66% Market Closed
Market Cap: 62.8m USD
Have any thoughts about
Verrica Pharmaceuticals Inc?
Write Note

Gross Margin
Verrica Pharmaceuticals Inc

74.1%
Current
36%
Average
48.4%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
74.1%
=
Gross Profit
6.8m
/
Revenue
9.2m

Gross Margin Across Competitors

Country US
Market Cap 62.8m USD
Gross Margin
74%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 729.3B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 2.6T DKK
Gross Margin
85%
Country US
Market Cap 347.8B USD
Gross Margin
69%
Country US
Market Cap 248.3B USD
Gross Margin
77%
Country CH
Market Cap 197.2B CHF
Gross Margin
73%
Country UK
Market Cap 159B GBP
Gross Margin
82%
Country CH
Market Cap 169.7B CHF
Gross Margin
75%
Country US
Market Cap 149.4B USD
Gross Margin
71%
No Stocks Found

Verrica Pharmaceuticals Inc
Glance View

Market Cap
62.8m USD
Industry
Pharmaceuticals

Verrica Pharmaceuticals, Inc. engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. The company is headquartered in West Chester, Pennsylvania and currently employs 38 full-time employees. The company went IPO on 2018-06-15. The firm is focused on developing and commercializing treatments for skin diseases. The firm's lead product candidate, VP-102, is a drug-device combination of its topical solution of cantharidin, a widely recognized, naturally sourced agent to treat topical dermatological conditions, administered through its single-use precision applicator. The company is developing VP-102 for the treatment of molluscum contagiosum (molluscum), a highly contagious and primarily pediatric viral skin disease, external genital warts and common warts. The company also intends to develop its second cantharidin-based product candidate, VP-103, for the treatment of plantar warts, which are warts located on the bottom of the foot. The company also intends to develop its third product candidate, LTX-315, for the treatment of dermatological oncology indications, including non-metastatic melanoma and non-metastatic Merkel cell carcinoma.

VRCA Intrinsic Value
1.338 USD
Undervaluation 48%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
74.1%
=
Gross Profit
6.8m
/
Revenue
9.2m
What is the Gross Margin of Verrica Pharmaceuticals Inc?

Based on Verrica Pharmaceuticals Inc's most recent financial statements, the company has Gross Margin of 74.1%.